Generation of Innovative Cancer Immune Gene and Cell Therapy Technology by Replicating Virus and CAR-T
| Project/Area Number |
20K21580
|
|---|
| Research Category |
Grant-in-Aid for Challenging Research (Exploratory)
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Medium-sized Section 52:General internal medicine and related fields
|
|---|
| Research Institution | Kagoshima University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
三井 薫 鹿児島大学, 医歯学域医学系, 准教授 (40324975)
伊地知 暢広 鹿児島大学, 医歯学域医学系, 助教 (80380624)
|
|---|
| Project Period (FY) |
2020-07-30 – 2023-03-31
|
| Project Status |
Completed (Fiscal Year 2022)
|
| Budget Amount *help |
¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
Fiscal Year 2021: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Fiscal Year 2020: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
|
|---|
| Keywords | 腫瘍溶解性ウイルス / CAR-T / 癌免疫治療 |
|---|
| Outline of Research at the Start |
従来のCAR-T（キメラ抗原受容体T細胞）は、血液腫瘍に劇的治療効果を示すが、固形腫瘍には十分な効果を示していない。本研究では新規のm-CRA（多因子で精密に癌特異標的治療する増殖制御型アデノウイルス）で、がん細胞に幾つかの目的遺伝子を導入する。新規のCAR-T細胞や、細胞障害性T細胞(CTL)が、がん局所に集積、治療して免疫が誘導される。m-CRAとCAR-Tの両者のがん細胞殺傷作用が相乗的に強力に誘導され、CTLも効率よく誘導できる、全く新しい治療法の開発を行う。
|
| Outline of Final Research Achievements |
CAR-T has shown dramatic therapeutic effects on hematologic tumors, but has not shown sufficient effects on solid tumors. In the field of gene/virus therapy, the principal investigator first developed an original cancer immune gene therapy method, and then developed an original next-generation OV, m-CRA technology. The first product, Surv.m-CRA (survivin-responsive m-CRA) has shown superior performance to conventional and competing technologies, and first-in-human investigator-initiated clinical trials was done. The objective of this study is to generate a cancer immunotherapy technology that can efficiently induce systemic anti-tumor immunity by integrating m-CRA and CAR-T technology. The research was conducted by constructing materials, as well as by establishing analyze systems, and conducting experiments, focusing on the development of the basic m-CRA technology.
|
| Academic Significance and Societal Importance of the Research Achievements |
免疫チェックポイント阻害剤の開発で、癌免疫療法は有望の癌治療戦略と認識されたが、次世代の癌免疫治療として世界的に開発が進むOVとCAR-Tは、本邦では独自の基盤技術開発が遅れている。本研究はm-CRAとCAR-Tの相乗効果を創出する新技術の創出を試みたものであり、科学的な挑戦性、先駆性、独創性が高い。また最終的に革新的な癌免疫治療の創出と実用化に繋がれば、癌の制圧にも貢献できる社会的意義を持つ。
|
Report
(4 results)
Research Products
(28 results)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] Survivin-responsive Conditionally Replicating Adenovirus for Patients with Advanced Sarcoma Demonstrated Potent and Long-term Efficacy and High Safety in Phase 1 Clinical Trial.2020
Author(s)
Satoshi Nagano, Toshitaka Futagawa, Eriko Sumi, Nobuhiro Ijichi, Munekazu Yamakuchi, Masanori Nakajo, Teruto Hashiguchi, Yasuo Takeda, Takashi Yoshiura, Akira Shimizu, Muneo Takatani, Setsuro Komiya, Ken-ichiro Kosai.
Organizer
2020 ASCO Annual Meeting.
Related Report
Int'l Joint Research
-
-
-
-
-
-
-
-
